Physician profile
Deepa Abraham
NPI 1447250568
$2,985.42
in general payments reported to CMS, 2019-2025
11 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $139 · 2022: $421 · 2023: $284 · 2024: $1,310 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Travel and Lodging: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.35 |
| Travel and Lodging | $852.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,969.91 | 2022-2025 | Clareon, Tryptyr, Voyager Dslt |
| Allergan, INC. | $161.44 | 2019 | |
| Aerie Pharmaceuticals, INC. | $158.79 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $125.00 | 2023 | Miebo |
| Spark Therapeutics, INC. | $124.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2025 | Syfovre |
| Rxsight INC | $124.82 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Abbvie INC. | $78.82 | 2024 | |
| Glaukos Corporation | $55.64 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $36.54 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $24.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.